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Resumo
Introdução: Este estudo examinou os padrões de uso de drogas 
e os sintomas psiquiátricos de ansiedade e depressão entre 
brasileiros não heterossexuais usuários de ecstasy e/ou LSD 
e comparou os achados com aqueles relatados por seus pares 
heterossexuais.
Método: Este estudo transversal empregou amostragens 
direcionadas e abordagens de mapeamento etnográfico através de 
entrevistas presenciais realizadas em bares e festivais de música 
eletrônica usando uma versão adaptada e semiestruturada do 
questionário de Avaliação Global de Necessidades Individuais. A 
amostra incluiu 240 adultos jovens do sexo masculino e feminino 
que haviam usado ecstasy e/ou LSD nos 90 dias anteriores à 
entrevista e que não estavam em tratamento para abuso de 
álcool e drogas.
Resultados: Dos 240 sujeitos incluídos (idade média: 22,9±4,5 
anos), 28,7% eram homossexuais ou bissexuais. A análise de 
regressão multivariada mostrou que a prevalência de sintomas 
de depressão nos últimos 12 meses no grupo não heterossexual 
foi 37% superior à dos heterossexuais [razão de prevalência 
(RP) = 1,79; intervalo de confiança de 95% (IC95%) 1.03-3.11; 
p=0,037].
Conclusão: Estratégias devem ser desenvolvidas para avaliar 
e abordar as necessidades individuais, e as abordagens de 
tratamento devem ser adaptadas para sintomas depressivos em 
usuários de drogas jovens e não heterossexuais. 
Descritores: Ansiedade, depressão, sintomas psiquiátricos, não 
heterossexuais, drogas sintéticas.
Abstract
Background: This study examined drug use patterns and 
psychiatric symptoms of anxiety and depression among young 
Brazilian sexual minority ecstasy and LSD users and compared 
findings with those reported for their heterosexual peers. 
Method: This cross-sectional study employed targeted sampling 
and ethnographic mapping approaches via face-to-face 
interviews conducted at bars and electronic music festivals using 
an adapted, semi-structured version of the Global Appraisal of 
Individual Needs questionnaire. The sample comprised 240 male 
and female young adults who had used ecstasy and/or LSD in the 
90 days prior to the interview and who were not on treatment for 
alcohol and drug abuse. 
Results: Of the 240 subjects enrolled (mean age: 22.9±4.5 
years), 28.7% were gay or bisexuals. Multivariate regression 
analysis showed that the prevalence of depression symptoms in 
the past 12 months in the sexual minority group was 37% higher 
than among heterosexuals (prevalence ratio [PR]=1.79; 95% 
confidence interval [95%CI] 1.03-3.11; p=0.037). 
Conclusion: Strategies should be developed to assess and 
address individual needs and treatment approaches should 
be tailored to address depressive symptoms in young, sexual 
minority club drug users. 
Keywords: Anxiety, depression, psychiatric symptoms, sexual 
minority, synthetic drugs.
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Introduction
Some studies suggest that young sexual minority 
individuals disproportionately experience mental health 
problems, particularly diagnoses of depression and 
anxiety,1 including suicidal thoughts and behaviors, self-
mutilation, and addiction, as well as other psychiatric 
conditions, when compared with heterosexual 
individuals.2 Lifestyle, emotional and behavioral factors 
(including feelings of discrimination), excessive tobacco 
and other drug use, body image concerns, and extreme 
sexual promiscuity, among other aspects, may act as 
important factors3 to increase the risk of mental health 
disorders as well as substance abuse and sexually 
transmitted infections, including HIV.3-7 Mood disorders 
co-occurring with substance use and other risk behaviors 
increase social and occupational impairments, as well 
documented in several studies conducted, particularly 
in the USA and Europe.8 
A representative study performed in England by 
Chakraborty et al. with a sexual minority population 
identified higher levels of neurotic disorder (odds ratio 
[OR]=1.47), depressive episodes (OR=1.80), obsessive 
compulsive disorder (OR=2.24), alcohol (OR=2.05) 
and drug dependence (OR=1.70), as well as a higher 
prevalence of consultations with psychiatrists (OR=1.46) 
when compared with the heterosexual group.9 Another 
study investigating the prevalence of mental disorders 
and substance abuse revealed that non-heterosexuals 
had twice the risk of suicide attempts compared to 
heterosexual individuals, and showed a prevalence of 
depression and anxiety disorders 1.5 times higher than 
the general population.10 A systematic review6 found that, 
in addition to having an increased risk of depression and 
anxiety disorders and suicide attempts, non-heterosexuals 
had a higher risk of drug addiction (relative risk range: 
1.51 to 4.00) than the general population.11 
Although a number of studies have found correlations 
between sexual minority, drug use and psychiatric 
symptoms, few have included developing country 
sexual minorities that are also synthetic drug users.12 
Information about the mental health of non-heterosexual 
individuals, particularly in developing countries such as 
Brazil, is still inconclusive, whether due to the difficulties 
recruiting samples or the unwillingness of people to be 
open about their sexual orientation. The majority of 
studies have been conducted in the USA,12-15 Europe,16,17 
and Australia.18 Approaches to sexual minority groups 
are pretty diverse across countries, once prejudice and 
social stigma are driven by sociocultural factors.19 
This study assesses drug use patterns and 
psychiatric symptoms of anxiety and depression among 
young Brazilian sexual minority ecstasy and LSD users 




The present data were drawn from a larger 
observational study that recruited and enrolled 240 
club-goers in Porto Alegre, a state capital and large 
metropolitan area in southern Brazil. Participants 
were recruited from March to July 2010 using targeted 
sampling and ethnographic mapping. Eligibility criteria 
were: a) reported use of ecstasy, LSD or both at least 
once within the past 90 days; and b) no current drug or 
alcohol treatment.
The project staff and key informants in the club 
scene mapped the main nightclubs and rave parties 
where potential participants were known to gather. 
Potential participants were approached and invited 
to participate in the study. Face-to-face interviews 
that lasted about 15 minutes were conducted in loco 
to assess inclusion criteria. Those who met all criteria 
were invited to participate in a more detailed interview 
and other data collection procedures. Field interviewers 
were trained to collect data, with particular emphasis 
on elements of rapport, street terminology of drug 
use, and confidentiality and privacy of the information 
obtained. To ensure the quality of the data collected, 
the staff was trained to avoid interviewing visibly 
intoxicated individuals, due to concerns about both data 
validity and capacity to consent. All interview data were 
recorded using brief paper and pencil questionnaires.
After providing written informed consent, the 
participants were interviewed using an adapted version 
of the Global Appraisal of Individual Needs (GAIN-I) 
instrument (http://gaincc.org/GAINI).20 At the end of 
the interview, they received a lunch voucher (US$ 20) 
as a compensation for their participation.
The study was approved by the University of 
Delaware Institutional Review Board and by the 
Institutional Review Board and Research Ethics 
Committee of Hospital de Clínicas de Porto Alegre (CAEE 
no. 22864113.6.0000.5327). 
Instrument
A brief screening form based on studies conducted 
in the U.S. with similar populations21,22 was developed 
to identify eligible participants. The instrument used 
for subsequent primary data collection from selected 
individuals was an abbreviated version of GAIN-I, 
developed for brief intercept interviewing in street 
locations and adapted to the Brazilian context.20 
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The GAIN-I was validated and has been used to 
interview both adolescents and adults in a variety of 
settings, including synthetic drug users.21 GAIN-I results 
have provided the main clinical and research measures 
in many National Institute on Drug Abuse (NIDA)-funded 
multicenter studies. The original version of the instrument 
has eight sections: demographic characteristics; 
information regarding substance use patterns; physical 
health; risk behaviors; mental health; environment; 
legal; and vocational. The adapted version used in the 
present study was shortened since it was to be used 
for brief intercept interviewing in street locations. The 
following sections were kept in the final shortened format 
and adapted to the Brazilian context: 1) substance use; 
2) mental health; 3) risk behaviors; and 4) vocational. 
Questions related to basic demographic information 
included age, gender, education (years of schooling), and 
monthly individual income. Substance use was assessed 
by asking participants how many times a particular 
substance was used in the 90 days before the interview, 
as well as during their lifetime. A comprehensive list of 
illicit drugs and their correspondent “street names” was 
presented to participants and included: alcohol, cannabis, 
inhalants, ecstasy, LSD, methamphetamine, and cocaine.
Mental health data collection focused on the 12 
months preceding the interview, and symptoms were 
classified according to the Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM-IV). 
The mental health section included three subscales: 
Anxiety and Fear Symptoms Scale (AFSS), Depression 
Symptoms Scale (DSS) and Traumatic Symptoms Scale 
(TSS). Anxiety symptoms were assessed using the 12 
items of the AFSS (e.g., “During the past 12 months, 
have you had significant problems feeling very anxious, 
nervous, tense, scared, panicked or like something bad 
was going to happen?”). Depressive symptoms were 
assessed using the 11 items of the DSS (e.g., “During 
the past 12 months, have you had significant problems 
with feeling very trapped, lonely, sad, blue, depressed, or 
hopeless about the future?”). Traumatic symptoms were 
assessed using the 12 items of the TSS (e.g., “When 
something reminds you of the past, do you become very 
distressed and upset?”). In the present study, only the 
data collected using DSS and AFSS are presented; TSS 
data are still undergoing analysis and will be the subject 
of future publications. All variables in the psychiatric 
symptom scales were dichotomous (yes/no questions). 
Data analysis
Categorical variables were presented as absolute and 
relative frequencies, and interval variables, as means 
and standard deviation or as medians and interquartile 
range (first and third quartiles). Psychiatric symptoms 
were classified, based on the number of symptoms 
reported in the 12 months before the interview, as 
mild, moderate, or clinically relevant. For anxiety, 
categories were: mild, 0-1 symptom; moderate, 2-6 
symptoms; and clinically relevant, 7-12 symptoms. 
For depression, categories were: mild, 0-1 symptom; 
moderate, 2-5 symptoms; and clinically relevant, 6 or 
more symptoms. 
For the purpose of logistic regression, the three 
categories of psychiatric symptoms (mild, moderate and 
clinically relevant) were treated as yes/no variables, 
i.e., the moderate and clinically relevant categories 
were considered as yes, and the mild category was 
considered as no. 
Data about drug use in the last 90 days were 
described as medians and interquartile ranges. The 
Mann-Whitney test was used for the comparison of the 
drug distribution profile in the two groups (heterosexual 
and sexual minority club goers). The level of significance 
was set at p<0.05.
Univariate Poisson regression was used to identify 
independent variables significantly associated with the 
study outcome. Variables with p<0.10 in the univariate 
model were considered eligible to enter the multivariate 
analysis. Collinearity diagnostics were analyzed between 
the adjustment variables. The variable age of inhalant 
use (p=0.085) was not included as an adjustment 
variable because 118 participants out of 240 reported 
inhalant use. Heterosexual participants were used as 
reference group for subsequent analyses. All analyses 
were adjusted for gender, education, age, lifetime 
cocaine use, and mean number of days of any drug use 
in the past 90 days.
Demographic characteristics, psychiatric symptoms 
of depression and anxiety over the past 12 months, 
substance use patterns over the past 90 days, and 
lifetime substance use were compared between sexual 
minority and heterosexual participants. Sexual minority 
participants were defined as those who reported their 
sexual orientation as gay, lesbian or bisexual in response 
to the item: “Which of the following best describes you?” 
The possible answers were (1) heterosexual or straight, 
(2) gay or lesbian, or (3) bisexual. 
Results
Demographic characteristics
Of the 240 subjects enrolled (mean age: 22.9±4.5), 
57.9% were men; 69% had between 5 and 8 years 
of schooling; 42.1% were employed; and 60% had a 
mean monthly income of up to US$ 602.80, about three 
times the monthly minimum wage in Brazil at the time 
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of the study. The number of heterosexual participants 
(n=171, 71.3%) was higher than the number of those 
reporting sexual minority orientation (n=69, 28.7%; gay 
or lesbian, 17%; bisexual, 11.7%). The characteristics of 
this subset of participants are described below.
The sexual minority group comprised 69 participants 
(28.7%), whose mean age was 22.7±4.95 years old; 
49.3% were men. The comparison of heterosexuals 
and sexual minority participants revealed no statistical 
differences in terms of demographic characteristics. Most 
non-heterosexual participants were studying, working, or 
both at the time of the interview (95.6%); 56.5% had a 
mean individual monthly income of up to US$ 602.08; and 
76.5% had between 5 and 8 years of schooling (Table 1).
Drug use
Lifetime prevalence of drug use in the overall 
sample (N=240) was highest for alcohol (99.6%) 
and cannabis (95.4%), followed by LSD (88.3%) and 
ecstasy (83.2%); 33.3% reported to have used both 
ecstasy and LSD on the same occasion. In addition, 
56.3% reported the use of inhalants, and 23.2%, 
of amphetamines. The median number of days of 
use of any drug in the 90 days before the interview 
was 21 days (interquartile range: 12.56 to 32.37). 
Lifetime cocaine use was reported by over half of the 
participants (55%), and 44% of these used cocaine in 
the 90 days before the interview.
In the sexual minority group, 98.6% used alcohol in 
the 90 days before the interview; also, 95.7% reported 
lifetime cannabis use, and 77.3% of these used it in 
the 90 days before the interview. The analysis of recent 
use (90 days) revealed that 79.4% used ecstasy, 
84.7% LSD, and 48.9% cocaine. Lifetime cocaine use 
(p=0.007) was significantly different between the 
groups (Table 2). 
Psychiatric symptoms
Univariate Poisson regression was used to determine 
which variables were independently associated with 
the primary outcome. The following anxiety and 
depression variables reaching p<0.10 were included 
in the multivariate model: (1) “feeling very anxious, 
nervous, tense, scared, panicked or like something 





pYes (n=69) No (n=171)
Age, mean ± standard deviation 22.99±4.54 22.70±4.95 23.10±4.38 0.545
Gender, n (%) 0.115
Female 101 (42.1) 35 (50.7) 66 (38.6)
Male 139 (57.9) 34 (49.3) 105 (61.4)
Income, n (%) 0.828
No income 42 (17.5) 13 (18.8) 29 (17.0)
Up to US$ 602.80* 143 (59.6) 39 (56.5) 104 (60.8)
More than US$ 602.80 55 (22.9) 17 (24.6) 38 (22.2)
Occupation, n (%) 0.885
Studying and working 48 (20) 14 (20.3) 34 (19.9)
Student 76 (31.7) 23 (33.3) 53 (31.0)
Employed 101 (42.1) 29 (42.0) 72 (42.1)
No study/no work 15 (6.3) 3 (4.3) 12 (7.0)
Education level (years of schooling), n (%) 0.277
>8 58 (24.3) 12 (17.6) 46 (26.9)
5-8 165 (69.0) 52 (76.5) 113 (66.1)
1-4 16 (6.7) 4 (5.9) 12 (7.0)




Heterosexual participants were used as the reference category. 
* US$ 1=R$ 1.63 at the time of the study.
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pYes (n=69) No (n=171)
Days of drug use* 21.41 [12.6-32.4] 24.3 [12.6-32.9] 21.12 [12.6-31.7] 0.711
Alcohol† 239 (99.6) 69 (100.0) 169 (99.4) >0.999
Age at onset of use* 14 [13-15] 13 [12-15] 14 [13-15] 0.775
Last use 0.676
More than 90 days 6 (2.5) 1 (1.4) 5 (2.9)
Within 90 days 233 (97.5) 68 (98.6) 165 (97.1)
Days of use within 90 days* 30 [16.3-50] 36 [23-50] 30 [15-50] 0.055
Cannabis† 227 (95.4) 66 (95.7) 161 (95.3) >0.999
Age at onset of use* 15 [14-17] 15 [14-17] 15 [14-17] 0.781
Last use >0.999
More than 90 days 53 (23.1) 15 (2.7) 38 (23.3)
Within 90 days 174 (76) 51 (77.3) 123 (75.5)
Days of use within 90 days* 36 [10-88] 32 [3.5-88] 36 [10-88] 0.633
Inhalants† 134 (56.3) 44 (63.8) 90 (53.3) 0.180
Age at onset of use* 16 [15-20] 17 [16-18] 16 [15-22] 0.085
Last use 0.552
More than 90 days 88 (56.8) 26 (56.5) 62 (56.9)
Within 90 days 44 (28.4) 16 (34.8) 28 (25.7)
Days of use within 90 days* 3 [1.0-10] 3 [1.5-22.5] 2.5 [1-7.8] 0.527
Ecstasy† 198 (83.2) 62 (89.9) 136 (80.5) 0.118
Age at onset of use* 18 [17-22] 18 [17-20] 18.5 [17-22] 0.220
Last use 0.235
More than 90 days 51 (25.1) 12 (19) 39 (27.9)
Within 90 days 148 (72.9) 50 (79.4) 98 (70)
Days of use within 90 days* 2 [1-6] 2 [1-9] 2 [1-6] >0.999
LSD† 211 (88.3) 57 (82.6) 154 (90.6) 0.129
Age at onset of use* 19 [17-21] 18 [17-20] 19 [17-21.75] 0.181
Last use 0.702
More than 90 days 31 (14.3) 7 (11.9) 24 (15.20)
Within 90 days 180 (82.9) 50 (84.7) 130 (82.3)
Days of use within 90 days* 2.5 [1-5] 3 [1-10] 2 [1-5] 0.153
Methamphetamine† 56 (23.5) 17 (25.0) 39 (22.9) 0.866
Age at onset of use* 19 [17-21] 18 [17-21.5] 19 [17-21] 0.951
Last use 0.578
More than 90 days 24 (26.4) 9 (29) 15 (25)
Within 90 days 30 (33.0) 8 (25.8) 22 (36.7)
Days of use within 90 days 2.5 [1-5.3] 3 [1-6] 2 [1-5] 0.743
Cocaine† 132 (55.2) 48 (69.6) 84 (49.4) 0.007‡
Age at onset of use* 18 [16-21] 18 [16-20] 18 [15-21] 0.392
Last use 0.546
More than 90 days 56 (37.6) 16 (34) 40 (39.2)
Within 90 days 65 (43.6) 23 (48.9) 42 (41.2)
Days of use within 90 days* 6.5 [3-24] 11 [4.3-46.5] 4.5 [2-18.8] 0.055
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bad was going to happen” (p=0.067); (2) “repeating 
an action over and over, or having thoughts that kept 
running over your mind” (p=0.004); (3) “problems 
with remembering, concentrating, making decisions, 
or having your mind go blank” (p=0.092); and (4) 
“getting into a lot of arguments and feeling the urge to 
shout, throw things, beat, injure and harm someone” 
(p=0.082). Of the variables included in the multivariate 
final model, “repeating an action over and over, or 
having thoughts that kept running over your mind” 
showed a higher prevalence in the sexual minority 
group than in the heterosexual group (prevalence ratio 
[PR]=1.703; 95% confidence interval [95%CI] 1.06-
2.73; p=0.028). 
Table 3 shows PRs (and respective 95%CIs) 
obtained at the univariate and multivariate Poisson 
models (univariate: anxiety or depression symptoms; 
multivariate: anxiety and depression symptoms). The 
prevalence of depression symptoms was 37% higher in 
the non-heterosexual than in the heterosexual group 
(PR=1.79; 95%CI 1.03-3.11; p=0.037).23 
Discussion
To the authors’ knowledge, this is the first study 
to assess drug use patterns and psychiatric symptoms 
of anxiety and depression among young Brazilian 
sexual minority ecstasy and LSD users and to compare 
findings with those obtained for their heterosexual 
peers. Self-reported identification as non-heterosexual 
was associated with a high prevalence of depression 
symptoms in the past 12 months,16,24,25 as well as with 
an anxiety manifestation of “repeating an action over 
and over, or having thoughts that kept running over 
your mind” (PR=1.703; 95%CI 1.06-2.73; p=0.028). 
A previous study conducted by Chakraborty et 
al.9 also found a high prevalence of depressive and 
anxiety symptoms in sexual minority individuals when 
compared with the heterosexual population. Other 
studies assessing mental health status among non-
heterosexuals revealed that anxiety, depression and 
relationship issues are the most frequent complaints at 
consultations in the public mental health system.7,26,27 
This suggests that the perceived discrimination faced 
by sexual minority subgroups acts as a social stressor 
in mental health problems.20,28 Our non-heterosexual 
participants reported more depressive symptoms over 
the past 12 months and showed a significantly higher 
result for compulsive behaviors and intrusive thoughts. 
In this regard, the multifactorial etiology of this result 
may be understood as one of the consequences of 
increased societal prejudice, stigma and discrimination 
to which this group is subjected. Diaz et al.29 studied 
a sample of Latino non-heterosexual men living in 
the United States and also found a high prevalence 
of depression. Particularly, in Latino non-heterosexual 
communities, prejudice and social stigma are driven 
by sociocultural factors, e.g., social disadvantage and 
expressive style. The lack of openness about sexual 
orientation may also explain the association between 
stigma, drug use and psychiatric symptoms.30 In our 
study, the comparison between groups revealed that 
anxiety and depression were more strongly present 
in the non-heterosexual group, even though anxiety 
is one of the most prevalent disorders in the general 
population. The association between symptoms of 
anxiety and depression may have affected the analyses, 
and therefore may have been a confounding factor. 
Clinically, anxiety and depression are often 
associated with the use of alcohol and drugs as 
a meaning of self-medication31 and as a relief for 






Univariate anxiety or 
depression symptoms
Multivariate anxiety and 
depression symptoms
Yes (n=69) No (n=171) PR 95%CI p PR 95%CI p
Anxiety
Yes* 159 49 (71.0) 110 (64.3) 1.13 0.71-1.79 0.604 0.84 0.50-1.41 0.511
No 81 20 (29.0) 61 (35.7) 1 1
Depression
Yes* 164 54 (78.3) 110 (64.3) 1.64 0.99-2.71 0.053 1.79 1.03-3.11 0.037
No 76 15 (21.7) 61 (35.7) 1 1
95%CI = 95% confidence interval; PR = prevalence ratio.
Univariate = composite model of having anxiety or depression symptoms, adjusted for lifetime cocaine use, gender, education, age, and mean number of days 
of drug use within 90 days.
Multivariate = composite model of having anxiety and depression symptoms adjusted for lifetime cocaine use, gender, education, age, and mean number of 
days of drug use within 90 days.
* Presence of any anxiety/depressive symptom in the 12 months prior to the interview.
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negative emotions. The desire to escape or avoid 
negative emotions30,32 has been found to be one of the 
psychological factors associated with drug use among 
non-heterosexual populations in general. In our study, 
sexual minority was suspected to be a risk factor for 
substance use; however, surprisingly, our study found 
similar rates of substance use (except for cocaine), 
age at onset of use, and number of days of drug use 
among heterosexual and sexual minority participants. 
Conversely, non-heterosexual individuals showed a 
higher prevalence of lifetime and recent use of cocaine 
than heterosexual participants. These findings are 
consistent with those reported by Newcomb et al.33: in 
that study, the prevalence of polysubstance use both in 
lifetime (64.4%) and in the past 6 months (53.0%) was 
higher among non-heterosexual individuals compared 
with heterosexual participants; conversely, a minority 
reported never having used any substances in their 
lifetime (12.9%) or in the past 6 months (17.6%). 
The high prevalence of cocaine use among non-
heterosexuals may be connected with sexual drive and 
with a predisposition to psychiatric comorbidities, as 
a way to temporarily move away from circumstances 
and factors that favor emotional stress. According to 
other studies, despite the predisposition to drug use 
in this population, drug use patterns differ over time 
and depend on geographical region,33 but little is 
currently known about differences in non-heterosexual 
subgroups across multiple substances, which limits 
our understanding of this phenomenon. Obtaining 
such information could help identify more susceptible 
regions, types of substances used, and use patterns 
to be targeted in prevention programs. Studies have 
often focused on the prevalence or frequency of use 
of a single substance, class of drugs, or composite 
measures,20,26 which limits the possibility of comparing 
prevalence rates of use of multiple substances.
Some limitations of the present study should 
be considered. One important limitation for the 
comparability of our data – which is also strength of the 
study – is the lack of previous similar studies conducted 
either in Brazil or elsewhere in the world. Also, 
individuals were selected using convenience sampling; 
therefore, our sample may not be representative of 
the sexual minority club-going population subgroup. 
Nonetheless, the consistency between our findings and 
those reported in the relevant literature suggests at 
least some degree of similarity between our sample and 
other non-heterosexual drug-using populations. Data 
collected at nightclubs, parties and festivals are known 
to be a good source for prevalence studies.34-37 However, 
sample size and data collection site may affect result 
generalizability. For instance, the choice of collection 
site may result in a bias toward including individuals 
under the effect of alcohol or other substances, which 
may compromise data validity. However, our staff 
was trained to avoid interviewing visibly intoxicated 
individuals precisely due to concerns about both data 
validity and capacity to consent.
In conclusion, our findings suggest that strategies 
should be developed to assess and address individual 
needs and to motivate sexual minority people to seek 
treatment. In addition, the results show that substance 
use in this population is potentially more severe than 
in the heterosexual population, as demonstrated by 
the higher rates of drug use and number of days of 
drug use. 
Several types of treatment, such as medication, 
psychotherapy, gay counseling and self-help websites, 
are available for this population. Approaches that take 
into consideration cultural differences and minority 
groups should be implemented to prevent and treat 
drug use. Social isolation and drug use, as a cause or 
consequence of depression and anxiety, may worsen the 
course of the disease. Furthermore, sexual minorities 
need to be taught strategies to cope with prejudice, 
and public health services should be able to provide 
family and community support when these individuals 
are victimized. 
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